Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort

Miriam Retuerto-Guerrero, Ignacio González Fernández, Mirian Alejo Ramos, Ismael González Fernández, Andrea Vélez Blanco, Anibal Martin Sanz, Octavio Miguel Rivero-Lezcano, Elvira Díez-Álvarez · 2026

Read Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort by Miriam Retuerto-Guerrero, Ignacio González Fernández, Mirian Alejo Ramos, Ismael González Fernández, Andrea Vélez Blanco, Anibal Martin Sanz, Octavio Miguel Rivero-Lezcano, Elvira Díez-Álvarez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13536120.txt.

Description

Miriam Retuerto-Guerrero and co-workers review outcomes of GLP-1 drugs in rheumatology patients, in a 2026 single-center study. These drugs, first used for diabetes and weight, are now common in joint clinics where obesity and diabetes are frequent. Real-world data in this setting were limited.

The study followed one hundred nineteen outpatients over a year of treatment. Weight fell steadily, reaching an average loss near eight percent at twelve months, and blood sugar control improved. Cholesterol measures also got better. One inflammation marker fell clearly at twelve months, while another fell without reaching significance. Side effects were mainly stomach-related.

Catalog record

CREATORMiriam Retuerto-Guerrero, Ignacio González Fernández, Mirian Alejo Ramos, Ismael González Fernández, Andrea Vélez Blanco, Anibal Martin Sanz, Octavio Miguel Rivero-Lezcano, Elvira Díez-Álvarez
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13536120

Browse the full library · About the Tower of Babel